Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.

Khalid Al-FaraidyMousa AkbarMohamed ShehriMohammad AljarallahGamal Abdin HusseinRaja DashtiAhmad Al QudaimiFahad Al NouriZuhier AwanAhmed EssamAlaa Emara

Published in: PloS one (2023)

Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations.

Keyphrases

low density lipoprotein
primary care
open label
high fat diet
randomized controlled trial
stem cells
type diabetes
big data
general practice
cell therapy
insulin resistance
double blind
high fat diet induced